Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Australian Floating Rate ETF (FLOT) vs BIO-TECHNE Corp (TECH) Price & Performance

VanEck Australian Floating Rate ETFTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

VanEck Australian Floating Rate ETF vs BIO-TECHNE Corp — how do they compare? VanEck Australian Floating Rate ETF trades at $50.97, while BIO-TECHNE Corp trades at $71.67 (market cap $11.14B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while VanEck Australian Floating Rate ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.

FLOTTECH
Sector
Sector/ThematicHealth
52-Week High
$51.09$71.48
52-Week Low
$50.72$43.31
Market Cap
$11.14B
Enterprise Value
$11.22B
Dividend Yield
0.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Australian Floating Rate ETF

No Aura AI signal available yet.

BIO-TECHNE Corp

Bio-Techne Corporation (TECH) trades at $71.66, near its all-time high, following Merck KGaA's announced $73 per share cash acquisition offer, representing a 24% premium. The stock shows a bullish technical trend, while fundamental metrics reveal a high valuation with a P/E of 102.12 and a net income margin of 9.05%. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. Analyst consensus is evenly split between Buy and Hold, with a $67.75 price target below the current offer price.

The investment outlook is dominated by the pending acquisition by Merck KGaA. The primary opportunity is the realization of the $73 per share offer, providing a clear exit near current levels. Key risks include potential deal completion delays, regulatory scrutiny, and shareholder litigation questioning the fairness of the price. Should the deal fall through, the stock faces significant downside pressure given its stretched valuation and recent earnings volatility.

Returns comparison

Trailing returns across standard periods

About VanEck Australian Floating Rate ETF

FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.

Read more on FLOT

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH